CMMB
Chemomab Therapeutics Ltd.NASDAQHealthcare$1.56+6.41%ClosedMarket Cap: $9.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.05
P/S
0.00
EV/EBITDA
-0.28
DCF Value
$1.56
FCF Yield
-109.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-82.5%
ROA
-65.2%
ROIC
-77.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-2.0M | $-1.9M | $-0.24 | — |
| FY 2025 | $0.00 | -Infinity% | $-9.6M | $-9.1M | $-1.42 | — |
| Q3 2025 | $0.00 | NaN% | $-1.8M | $-1.7M | $-0.28 | — |
| Q2 2025 | $0.00 | -Infinity% | $-2.3M | $-2.1M | $-0.36 | — |
| Q1 2025 | $0.00 | NaN% | $-3.5M | $-3.3M | $-0.58 | — |
| Q4 2024 | $0.00 | NaN% | $-3.2M | $-3.0M | $-0.63 | — |
| FY 2024 | $0.00 | -Infinity% | $-14.7M | $-13.9M | $-3.12 | — |
| Q3 2024 | $0.00 | NaN% | $-3.7M | $-3.5M | $-0.80 | — |
| Q2 2024 | $0.00 | -Infinity% | $-3.8M | $-3.6M | $-1.01 | — |
| Q1 2024 | $0.00 | NaN% | $-4.0M | $-3.9M | $-1.10 | — |
| Q4 2023 | $0.00 | -Infinity% | $-3.8M | $-3.5M | $-1.06 | — |
| FY 2023 | $0.00 | -Infinity% | $-25.5M | $-24.2M | $-8.22 | — |